🇺🇸 FDA
Pipeline program

601 1.25mg

SSGJ-601-BRVO-III-01

Phase 3 small_molecule completed

Quick answer

601 1.25mg for Branch Retinal Vein Occlusion is a Phase 3 program (small_molecule) at Sunshine Biopharma with 2 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Branch Retinal Vein Occlusion
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials